Letrozol Amarox (Letrozole)

Letrozole blocks the aromatase enzyme (CYP19A1), preventing the conversion of androgens into estrogens. By lowering systemic estrogen levels, it deprives estrogen‑dependent breast cancer cells of a key growth signal, thereby inhibiting tumor proliferation.

The appropriate dose of Letrozol Amarox is determined by the prescribing clinician based on the patient’s clinical condition, treatment intent, and any relevant laboratory values. Specific dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Letrozol Amarox is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant.

To order Letrozol Amarox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozol Amarox (letrozole) is a third‑generation aromatase inhibitor with a high potency and a relatively long half‑life, offering once‑daily dosing. Compared with anastrozole or exemestane, letrozole often provides greater estrogen suppression, which may translate into slightly higher efficacy in certain patient populations, though safety profiles are broadly similar.

Letrozol Amarox tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

Letrozol Amarox is taken orally, usually with a glass of water. It is generally administered once daily, and patients should follow the timing and any food‑related instructions provided by their healthcare professional.

The most serious adverse events linked to Letrozol Amarox include osteoporosis or bone fractures due to prolonged estrogen depletion, severe liver injury, and thromboembolic events such as pulmonary embolism or deep‑vein thrombosis. Patients should be monitored regularly for these conditions.

Letrozol Amarox should not be used by premenopausal women, pregnant or breastfeeding individuals, patients with severe hepatic impairment, or those with known hypersensitivity to letrozole or any excipients. Caution is also advised in patients with a history of cardiovascular disease or bone disorders.